Vision Clarity Eye Drop

Description

NDC 71108-001-05. Life Vitality VISION CLARITY EYE DROPS are formulated with 1.0% glycerin as a lubricating agent. The product is presented in two vials, each containing 0.17 fl oz (5 ml), for a total net volume of 0.34 fl oz (10 ml). The formulation emphasizes integrity, quality, and purity, with a 100% quality guarantee.

Uses and Indications

This drug is indicated for use as a lubricant to prevent further irritation or to relieve dryness of the eye. It is also indicated for the temporary relief of discomfort associated with minor irritations of the eye, including those resulting from exposure to wind or sun.

Dosage and Administration

Healthcare professionals are advised to instill 1 or 2 drops of the medication in the affected eye(s) as needed. The frequency of administration should be determined based on the clinical condition of the patient and the response to treatment. It is important to ensure that the drops are administered in a sterile manner to prevent contamination.

Contraindications

Use of this product is contraindicated if the solution changes color or becomes cloudy, as this may indicate contamination or degradation of the product.

To prevent contamination, it is essential to avoid contact between the tip of the container and any surface.

Patients should discontinue use and consult a healthcare professional if they experience eye pain, changes in vision, persistent redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

Warnings and Precautions

For external use only. This product should not be utilized if the solution changes color or becomes cloudy, as this may indicate a compromise in its integrity.

When using this product, it is imperative to avoid contamination. Users must refrain from touching the tip of the container to any surface. After each use, the cap should be securely replaced to maintain product sterility.

Users are advised to discontinue use and consult a healthcare professional if they experience any of the following: eye pain, changes in vision, persistent redness or irritation of the eye, or if the condition worsens or does not improve within 72 hours.

In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended without delay.

Side Effects

Patients should be aware that the product is intended for external use only. It is crucial to avoid using the solution if it changes color or becomes cloudy, as this may indicate a compromised formulation.

During use, to prevent contamination, patients should refrain from touching the tip of the container to any surface and should ensure that the cap is replaced immediately after use.

Patients are advised to discontinue use and consult a healthcare professional if they experience any of the following: eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours.

In the event that the product is swallowed, it is imperative to seek medical assistance or contact a Poison Control Center without delay.

Drug Interactions

There are no specific drug interactions reported for this medication. Additionally, no laboratory test interactions have been identified in the available data. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Vision Clarity Eye Drop (glycerin). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this product out of reach of children. In the event that the product is swallowed, it is crucial to seek medical assistance or contact a Poison Control Center immediately.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any adverse effects or changes in therapeutic response, given the lack of targeted data for this population.

Pregnancy

Pregnant patients should be aware that no specific information regarding the use of this product during pregnancy is provided in the drug insert. There are no statements indicating whether the product is contraindicated in pregnancy or any associated risks to the fetus. Additionally, no dosage modifications or special precautions regarding use during pregnancy are mentioned. Healthcare professionals should consider the lack of data when advising women of childbearing potential and weigh the potential benefits against any unknown risks.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or lactation considerations. Healthcare professionals should exercise caution and consider the potential risks and benefits when prescribing this medication to lactating mothers. Further research may be necessary to fully understand the implications for breastfed infants.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the product is ingested, healthcare professionals should advise patients or caregivers to seek medical assistance or contact a Poison Control Center without delay.

Prompt action is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific product and the amount ingested; therefore, a thorough assessment by a medical professional is recommended.

Management procedures may include supportive care and symptomatic treatment as necessary. It is imperative that healthcare providers remain vigilant and prepared to address any complications that may arise from an overdosage scenario.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's safety profile in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed. It is important to instruct patients not to use the product if the solution changes color or becomes cloudy, as this may indicate a loss of efficacy or safety.

When using the product, patients should be informed to avoid contamination by not touching the tip of the container to any surface. Additionally, they should be reminded to replace the cap securely after each use to maintain the integrity of the solution.

Patients should be counseled to discontinue use and consult a doctor if they experience any of the following: eye pain, changes in vision, continued redness or irritation of the eye, or if their condition worsens or persists for more than 72 hours. This guidance is essential for ensuring patient safety and effective use of the product.

Storage and Handling

The product is supplied in a container that must be stored in a refrigerator, ensuring that it remains at a temperature range suitable for preservation. It is critical to avoid freezing the product, as this may compromise its integrity. The container should be kept in a dark, cool place, away from direct sunlight to maintain optimal conditions.

Once the container has been opened, it is essential to discard both the container and any remaining contents after 30 days to ensure safety and efficacy. Users should also pay attention to the expiration date marked on the container and utilize the product before this date.

For proper administration, it is advised that contact lenses be removed prior to drop instillation. Lenses can be reinserted after a waiting period of 10 minutes to ensure the effectiveness of the treatment.

Additional Clinical Information

The medication is administered via the ophthalmic route, with a recommended dosage of 1 or 2 drops instilled in the affected eye(s) as needed. Clinicians should advise patients to remove contact lenses prior to instillation and to wait at least 10 minutes before reinserting them. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for Vision Clarity Eye Drop, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)